Michael Bringuier

Dr. Michael Bringuier


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
RGRomain Geiss
Romain Geiss
LSLucrezia Sebaste
Lucrezia Sebaste
RVRémi Valter
Rémi Valter
JPJohanne Poisson
Johanne Poisson
SMSoraya Mebarki
Soraya Mebarki
Éléna PaillaudÉléna Paillaud
Éléna Paillaud
Radical cystectomy is the standard of care for localized bladder cancer but is associated with high morbidity and mortality rates—especially among older patients with comorbidities. The association between geriatric assessment parameters on post-operative complications and discharge has not previously been investigated. The present analysis of the Elderly Cancer Patient (ELCAPA) prospective cohort included all patients aged ≥70 having undergone a geriatric assessment and then radical cystectomy for localized muscle-invasive bladder cancer between 2007 and 2018. The primary endpoint was the proportion of patients with one or more complications in the first 30 days after cystectomy. The secondary endpoints were the length of hospital stay (LOS), the 30-day mortality, and discharge rates. Sixty-two patients (median age: 81; range: 79–83.8) were included. The 30-day complication rate was 73%, and 49% of the patients had experienced a major complication, according to the Clavien-Dindo classification. The 30-day mortality rate was 4%. None of the geriatric, oncological, or laboratory parameters were significantly associated with the occurrence or severity of complications. The median (interquartile range) LOS was 18 days (15–23) overall and was longer in patients with complications (19 days vs. 15 days in those without complications; p = 0.013). Thirty days after cystectomy, 25 patients (53%) had been discharged to home and 22 (47%) were still in a rehabilitation unit. In a univariate analysis, a Geriatric-8 score ≤ 14, a loss of one point on the Activities of Daily Living Scale, anemia, at least one grade ≥ 3 comorbidity on the Cumulative Illness Rating Scale-Geriatric, and an inpatient geriatric assessment were associated with a risk of not being discharged to home. In older patients having undergone a geriatric assessment, radical cystectomy is associated with a high complication rate, a longer LOS, and functional decline at 30 days.

21 March 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
CMClaudia Martinez-Tapia
Claudia Martinez-Tapia
KRKevin Rougette
Kevin Rougette
VFVirginie Fossey-Diaz
Virginie Fossey-Diaz
TCTristan Cudennec
Tristan Cudennec
CTCherifa Taleb
Cherifa Taleb
Éléna PaillaudÉléna Paillaud
Éléna Paillaud
Older cancer patients have an elevated risk of sarcopenia. The aim was to estimate the prevalence of four criteria for sarcopenia case finding, assessment, diagnosis, and severity determination: abnormal strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F), low hand-grip strength (HGS), low arm circumference (AC, a muscle mass proxy), and low physical performance (PP). Sarcopenia (low HGS and AC) and severe sarcopenia (low HGS, AC, and PP) and their predictive values for 6-month mortality were estimated in the whole population and by metastatic status. We analyzed data from the NutriAgeCancer French nationwide study of cancer patients aged ≥70 referred for geriatric assessment before anti-cancer treatment. We performed Cox proportional hazards analysis for each criterion separately and all criteria combined. Overall, 781 patients from 41 geriatric oncology clinics were included (mean age: 83.1; females: 53%; main cancer types: digestive (29%) and breast (17%); metastases: 42%). The prevalence of abnormal SARC-F, low HGS, a low AC, low PP, sarcopenia, and severe sarcopenia were, respectively, 35.5%, 44.6%, 44.7%, 35.2%, 24.5%, and 11.7%. An abnormal SARC-F and/or low HGS, sarcopenia, and severe sarcopenia were associated with 6-month mortality in patients with metastases (adjusted hazard ratios [95% confidence interval]: 2.72 [1.34–5.49], 3.16 [1.48–6.75] and 6.41 [2.5–16.5], respectively). Sarcopenia was strongly predictive of 6-month mortality in patients with metastatic cancer.

24 November 2023 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
LRLayal Rached
Layal Rached
AGArthur GERAUD
Arthur GERAUD
MFMaxime Frélaut
Maxime Frélaut
ZTZoé AP THOMAS
Zoé AP THOMAS
VGVincent Goldschmidt
Vincent Goldschmidt
CBCapucine Baldini
Capucine Baldini

28 June 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
Nicolò Matteo Luca BattistiNicolò Matteo Luca Battisti
Nicolò Matteo Luca Battisti
NGNienke de Glas
Nienke de Glas
ESEnrique Soto-Pérez-De-Celis
Enrique Soto-Pérez-De-Celis
GLGabor Liposits
Gabor Liposits
MBMichael Bringuier
Michael Bringuier
EBEtienne Brain
Etienne Brain

1 February 2024 in Age and Ageing
Verified
Journal Article
Open access
PDF file
MHMeoïn Hagège
Meoïn Hagège
MBMichael Bringuier
Michael Bringuier
CMClaudia Martinez-Tapia
Claudia Martinez-Tapia
CCchristos chouaid
christos chouaid
CHCarole HELISSEY
Carole HELISSEY
FCFlorence Canouï‐Poitrine
Florence Canouï‐Poitrine
Background: Few studies of the under-representation of older adults in cancer clinical trials (CTs) have encompassed the entire pathway from a trial being available in a cancer centre to the patient’s invitation to participate and then agreement or refusal to participate. Objectives: The study’s primary objective was to evaluate CT non-invitation and refusal rates. The secondary objectives were to identify factors associated with non-invitation and refusal and to assess experiences of CT participation from the patients’ and professionals’ perspectives. Methods: Here, we used mixed methods and a socio-epidemiological approach to analyse reasons for the non-participation of eligible older patients with a solid cancer in cancer CTs in France. Results: We found that non-invitation and low CT participation are mainly related to the patients’ sociodemographic characteristics and living conditions (such as social isolation, being single, divorced or widowed, not having children and the absence of close family members) and the healthcare professionals’ perceptions of insufficient informal support or a high homecare requirement. Conclusion: Our results suggest that efforts to increase fair inclusion and the participation of older adults in CTs should target the physician–patient relationship, the medical profession and hospital funding, rather than the patient alone.

7 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
NONadia Oubaya
Nadia Oubaya
Pierre Louis SoubeyranPierre Louis Soubeyran
Pierre Louis Soubeyran
NRNicoleta Reinald
Nicoleta Reinald
MFMarianne Fonck
Marianne Fonck
MAMylène Allain
Mylène Allain
FCFlorence Canouï‐Poitrine
Florence Canouï‐Poitrine
Background: The prognostic assessment of older cancer patients is complicated by their heterogeneity. We aimed to assess the prognostic value of routine inflammatory biomarkers. Methods: A pooled analysis of prospective multicenter cohorts of cancer patients aged ≥70 was performed. We measured CRP and albumin, and calculated Glasgow Prognostic Score (GPS) and CRP/albumin ratio. The GPS has three levels (0 = CRP ≤ 10 mg/L, albumin ≥ 35 g/L, i.e., normal values; 1 = one abnormal value; 2 = two abnormal values). One-year mortality was assessed using Cox models. Discriminative power was assessed using Harrell’s C index (C) and net reclassification improvement (NRI). Results: Overall, 1800 patients were analyzed (mean age: 79 ± 6; males: 62%; metastases: 38%). The GPS and CRP/albumin ratio were independently associated with mortality in patients not at risk of frailty (hazard ratio [95% confidence interval] = 4.48 [2.03–9.89] for GPS1, 11.64 [4.54–29.81] for GPS2, and 7.15 [3.22–15.90] for CRP/albumin ratio > 0.215) and in patients at risk of frailty (2.45 [1.79–3.34] for GPS1, 3.97 [2.93–5.37] for GPS2, and 2.81 [2.17–3.65] for CRP/albumin ratio > 0.215). The discriminative power of the baseline clinical model (C = 0.82 [0.80–0.83]) was increased by adding GPS (C = 0.84 [0.82–0.85]; NRI events (NRI+) = 10% [2–16]) and CRP/albumin ratio (C = 0.83 [0.82–0.85]; NRI+ = 14% [2–17]). Conclusions: Routine inflammatory biomarkers add prognostic value to clinical factors in older cancer patients.